RxDoctor Payments Data

Mark Gillett, MD

Family Medicine · Leawood, KSNPI 1497742886

Payments from drug & device makers

$9,518in general payments, 2019–2025

Across 690 payments — averaging $13.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$976
  • Amgen$731
  • AstraZeneca$584
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$9,502100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,518 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$10,948
Medicare patients
45
Services billed
140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide34$58,638
OzempicSemaglutide16$22,148
JardianceEmpagliflozin16$20,915
FarxigaDapagliflozin Propanediol16$16,902
MyrbetriqMirabegron12$5,306
Probenecid34$3,803
Atorvastatin Calcium211$1,881
Levothyroxine Sodium175$1,701
Duloxetine Hcl41$1,444
Gabapentin80$1,326
Lansoprazole13$1,318
Tamsulosin Hcl99$1,314
Ezetimibe65$1,151
Fluticasone Propionate57$1,135
Potassium Chloride60$1,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$1,080$58,63834 claims
Novo NordiskOzempic$976$22,14816 claims
Boehringer IngelheimJardiance$426$20,91516 claims
AstraZenecaFarxiga$584$16,90216 claims
Astellas Pharma US IncMyrbetriq$32$5,30612 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$84$1,701175 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Leawood

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →